case_images: PMC4377453_01
case_images: PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
case_images: CRIONM2015-471861.001.jpg
case_images: PMC4377453_03_CRIONM2015-471861.001.jpg
case_images: fig1
case_images: Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
case_images: PMC4377453_02
case_images: PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
case_images: CRIONM2015-471861.001.jpg
case_images: PMC4377453_03_CRIONM2015-471861.001.jpg
case_images: fig1
case_images: Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
case_images: PMC4377453_03
case_images: PSA plot for each patient and arrows indicate the initiation of combination therapy with metformin and/or Zyflamend (x-axis: time, y-axis: the value of PSA).
case_images: CRIONM2015-471861.001.jpg
case_images: PMC4377453_03_CRIONM2015-471861.001.jpg
case_images: fig1
case_images: Incredibly, his PSA decreased with the combined treatment (arrow, Figure 1(c)).
case_images: CT of the abdomen in case #3 revealed liver metastases (a) before the treatment and (b) after 17 months of treatment.
case_images: CRIONM2015-471861.002.jpg
case_images: PMC4377453_03_CRIONM2015-471861.002.jpg
case_images: fig2
case_images: CT findings of liver metastases and response to treatment are shown in Figure 2.
case_images: PMC4377453_04